Table 2. Subgroup meta-analysis categorization.
| Sub analyses | Subgroup | Regimens or IRI dose |
No. of identified trials |
|
|---|---|---|---|---|
| Neutropenia | Diarrhoea | |||
| By 5-FU status | +5FU (combined with 5-FU or analogue) | FOLFIRI, mFOLFIRI, IFL, FLIRI, Lv5FU-IR, mIFL, CapeIRI, IrFu, TEGAFIRI, XELIRI, UFT-Lv-IRI-OX, IRI-5FU-LV, IRI-5FU | 139, 10, 11, 12, 13, 15, 16, 17, 18, 21, 22, 24, 25 | 129, 10, 11, 12, 13, 15, 17, 18, 20, 24, 25, 26 |
| −5FU (no 5-FU or analogue) | IROX, IRI-raltitrexed, IRI-alone | 312, 15, 23 | 412, 15, 20, 23 | |
| By IRI dose | High IRI (medium and high dose) | >150 mg m−2 of IRI | 99, 12, 13, 15, 16, 17, 18, 21, 22 | 89, 12, 13, 15, 17, 18, 20, 26 |
| Low IRI (low dose) | <150 mg m−2 of IRI | 710, 11, 12, 16, 23, 24, 25 | 610, 11, 12, 23, 24, 25 | |
Abbreviations: CAPe, capecitabine; IRI, irinotecan; LV, leucovorin; OX(A), oxaliplatin; TEGAF, UFT/LV; UFT, uracil/tegafur; VEGF, vascular endothelial growth factor; XEL, xeloda; 5FU, 5-fluorouracil.